| Literature DB >> 27588239 |
Adhip Rahman1, Mohammad Tuhin Ali2, Mohammad Mahfuz Ali Khan Shawan3, Mohammed Golam Sarwar4, Mohammad A K Khan5, Mohammad A Halim6.
Abstract
A series of halogen-directed donepezil drugs has been designed to inhibit acetyl cholinesterase (AChE). Density Functional theory (DFT) has been employed to optimize the chair as well as boat conformers of the parent drug and modified ligands at B3LYP/MidiX and B3LYP/6-311G + (d,p) level of theories. Charge distribution, dipole moment, enthalpy, free energy and molecular orbitals of these ligands are also investigated to understand how the halogen-directed modifications impact the ligand structure and govern the non-bonding interactions with the receptors. Molecular docking calculation has been performed to understand the similarities and differences between the binding modes of unmodified and halogenated chair-formed ligands. Molecular docking indicated donepezil and modified ligands had non-covalent interactions with hydrophobic gorges and anionic subsites of AChE. The -CF3-directed ligand possessed the most negative binding affinity. Non-covalent interactions within the ligand-receptor systems were found to be mostly hydrophobic and π- stacking type. F, Cl and -CF3 containing ligands emerge as effective and selective AChE inhibitors, which can strongly interact with the two active sites of AChE. In addition, we have also investigated selected pharmacokinetic parameters of the parent and modified ligands.Entities:
Keywords: Alzheimer’s disease; Computer aided drug design; Density functional theory; Halogenation; Molecular docking; Nonbonding interactions
Year: 2016 PMID: 27588239 PMCID: PMC4987752 DOI: 10.1186/s40064-016-2996-5
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Fig. 1Chair and boat conformations of Donepezil
Fig. 2Optimized structure of Donepezil (D) Chair form and its halogenated derivatives (D1, D2, D3, D4 and D5) calculated at B3LYP/MidiX level of theory
The stoichiometry, electronic energy, enthalpy, Gibbs free energy in Hartree and dipole moment (Debye) of donepezil chair form and its derivatives
| Name | Stoichiometry | Electronic energy | Enthalpy | Gibbs free energy | Dipole moment |
|---|---|---|---|---|---|
| D_Chair | C24H29NO3 | −1204.887 | −1204.887 | −1204.970 | 2.58 |
| D1_Chair | C24H28FNO3 | −1303.572 | −1303.571 | −1303.656 | 3.82 |
| D2_Chair | C24H28ClNO3 | −1662.323 | −1662.322 | −1662.409 | 4.31 |
| D3_Chair | C24H28BrNO3 | −3766.304 | −3766.303 | −3766.390 | 3.78 |
| D4_Chair | C24H28INO3 | −8094.427 | −8094.427 | −8094.515 | 3.77 |
| D5_Chair | C25H28F3NO3 | −1540.040 | −1540.038 | −1540.132 | 1.64 |
Energy (atomic unit) gaps of HOMOs, LUMO, Gap, Hardness and Softness of all drugs
| Molecules |
|
|
|
|
|---|---|---|---|---|
| D_Chair | −0.21374 | −0.04412 | 0.16962 | 11.79106 |
| D1_Chair | −0.20857 | −0.05763 | 0.15094 | 13.26787 |
| D2_Chair | −0.21086 | −0.06102 | 0.14984 | 13.34757 |
| D3_Chair | −0.21101 | −0.06008 | 0.15093 | 13.25118 |
| D4_Chair | −0.21245 | −0.06621 | 0.14624 | 13.67614 |
| D5_Chair | −0.22074 | −0.04579 | 0.17495 | 11.43183 |
Free energy of binding values (Kcalmol−1) for ligand – AChE (at chair and boat form) systems obtained from flexible docking
| Systems | Free energy of binding | |
|---|---|---|
| Chair | Boat | |
| D-AchE | −11.1 | −11.5 |
| D1-AchE | −11.7 | −12.6 |
| D2-AchE | −11.5 | −12.0 |
| D3-AchE | −11.2 | −11.2 |
| D4-AchE | −10.2 | −11.0 |
| D5-AchE | −12.0 | −12.5 |
Selected non-covalent interactions among chair ligands D–D5 and AChE obtained via flexible docking
| Systems | Contacts | Bond distances (Å) | Systems | Contacts | Bond distances (Å) |
|---|---|---|---|---|---|
| D-AchE | C–H···O (Tyr70) | 2.66 | D3-TYMS | C–H···O (Asp72) | 2.94 |
| pi···pi (Trp84) | 3.85 | pi···pi (Trp84) | 3.90, 4.01 | ||
| pi···pi (Trp279) | 4.14 | pi···pi (Trp279) | 4.41, 5.61 | ||
| O···H–N (Phe288) | 2.84 | C–H···O (Ser286) | 2.81 | ||
| pi···pi (Phe330) | 4.03 | C–H···pi (Phe330) | 2.33 | ||
| pi···pi (Phe331) | 5.30 | pi···pi (Phe331) | 5.43 | ||
| pi···pi (Tyr334) | 4.65 | Alkyl···pi (Tyr334) | 4.54 | ||
| D1-AchE | C–H···O (Asp72) | 2.90 | D4-AChE | pi···pi (Trp84) | 3.75 |
| pi···pi (Trp84) | 3.87, 3.98 | Alkyl···pi (Phe330) | 4.92 | ||
| pi···pi (Trp279) | 4.41, 5.66 | Alkyl···pi (Phe331) | 5.20 | ||
| C–H···O (Ser286) | 2.90 | Alkyl···pi (Phe334) | 5.41 | ||
| C–H···pi (Phe330) | 2.40 | ||||
| Alkyl···pi (Phe331) | 5.41 | ||||
| Alkyl···pi (Tyr334) | 4.53 | ||||
| D2- AchE | C–H···O (Asp72) | 2.70 | D5-AChE | C–H···O (Asp72) | 2.74 |
| pi···pi (Trp84) | 3.89, 4.00 | pi···pi (Trp84) | 3.93, 4.17 | ||
| pi···pi (Trp279) | 4.35, 5.60 | F···H–C, F···C (Gly117) | 2.63, 3.17 | ||
| C–H···O (Ser286) | 3.00 | F···H–O (Tyr130) | 2.93 | ||
| O···H–N (Phe288) | 2.71 | F···O (Glu199) | 2.86, 2.91 | ||
| C–H···pi (Phe330) | 2.40 | pi···pi (Trp279) | 4.10 | ||
| pi···pi (Phe331) | 5.29 | C–H···O (Ser286) | 2.74 | ||
| pi···pi (Phe334) | 4.49 | O–H···N (Phe288) | 2.42 | ||
| pi···pi (Phe330) | 4.23 | ||||
| C–H···pi (Phe331) | 2.92 | ||||
| pi···pi (Tyr334) | 4.44 |
Brackets indicate the amino acid residues that are in contact with the ligands
Asp asparatic acid, Gly glycine, Glu glutamine, Phe phenylalanine, Ser serine, Trp tryptophan, Tyr tyrosine
Fig. 3Non-covalent interaction maps of a D (Chair)-AChE, b D1 (Chair)-AChE and c D5 (Chair)-AChE complexes
Fig. 4Superposition of the chair conformers of D (green), D1 (white) and D5 (blue) on the E2020 (red)/AChE crystal structure resolved at 2.5 Å
Selected pharmacokinetic parameters of Donepezil (Chair Form) and its derivatives
| Parameters | Donepezil | D1 | D2 | D3 | D4 | D5 |
|---|---|---|---|---|---|---|
| Blood Brain Barrier | + (0.9953) | + (0.9931) | + (0.9921) | + (0.9911) | + (0.9887) | + (0.9941) |
| Human Intestinal Absorption | + (0.9566) | + (0.9962) | + (0.9963) | + (0.9946) | + (0.9802) | + (1.0000) |
| P-glycoprotein Inhibitor | Inhibitor (0.7641) | Inhibitor (0.8388) | Inhibitor (0.7572) | Inhibitor (0.8138) | Inhibitor (0.8185) | Inhibitor (0.7949) |
| Human Ether-a-go–go-Related (hERG) Gene Inhibition | Strong-inhibitor (0.5386) | Weak-inhibitor (0.6930) | Weak-inhibitor (0.5693) | Weak-inhibitor (0.6698) | Weak-inhibitor (0.6194) | Weak-inhibitor (0.6544) |
| Acute Oral Toxicity | III | III | III | III | III | III |
| Rat Acute Toxicity, LD50 (mol/Kg) | 3.0123 | 2.8808 | 2.8378 | 2.8435 | 2.8480 | 3.0139 |
| Ki (at 298 K, nM) | 7.442 | 2.705 | 3.789 | 6.285 | 33.955 | 1.631 |
Probability values related to each of the parameters are given in the parenthesis